A classic "coiled spring" scenario. I have a feeling while discussions are underway, a lot is still contingent upon sNDA filing for first line RCC and definitive (positive) interim results in HCC. EXEL management has to wait rather than hastily take the offer. Cabo as it is well positioned to grow very well and company has plenty of cash and future positive cash flow to support operations, so they should be shrewd and wait a few more months. The buy-out thought seems more and more probable in the $50+ range. But if EXEL can keep itself independent we may well be looking at $100 in 2-3 years. That's a fantastic return for all of us long time holders....for many a real possibility of retirement!!
Folks the fun is just starting. The action clearly indicates some talks are going on behind the scenes. This type of movement in share price in three days is more that just the data release news from Monday. We are clearly in the line of sight for some big pharma for a takeout. Dawn, you were 100% correct we will be bought give the action (this is just a pre-leakage). I suspect we will see a $3-$4 movement when the actual leak takes place otherwise we will just wake up one morning and read that EXEL has agreed to "XYZ" offer of $38-$40
Let's hope today will see a new 12 month high!!
Most of you guys are riding OMER too, right? Love EXEL and OMER.
Hairy G. Balls
Shorties -- give it up! efficacy will kill you!
Big boys really know how to make money on promising/growing companies. They take it down 25% in 5 weeks (after great earnings) and then wait for some news and bring it back up 16% in two days, making a killing on both sides. Us longs awaiting the "bigger" news can only watch from the sidelines and chuckle (and a few of us with dry powder added while it was down)!
Looks like the biotech sector continues its momentum today......EXEL is still very cheap here at $24 as more positive news is not too far away (including another strong qtl'y numbers on Aug 3rd)!
Hairy G. Balls
First time that EXEL advanced on a 12%+ ... hold for low $30's then a buyout will come! kaboom! no less than $70's by the Fall
New 52 week high in the cross hairs and hopefully hits today. The current qtr will probably be stronger than last qtr (which was their first profitable qtr operationally), so would think we're positioned to be near 27-28 range after earnings on Aug 3rd!
Hairy G. Balls
Buy me a beer! KABOOM! we will see $25's soon!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! boom!
Exelixis has generated explosive sales growth over the last four quarters, ranging from 354% to 680%. Quarterly revenue has risen from $36 million to nearly $81 million during that time. Earnings growth has ranged from 105% to 167% over the last three reports, but note that those gains are based on comparisons to year-over-year quarters with no earnings. Institutional investors have taken notice, and the number of funds with a position in Exelixis has risen in each of the last four quarters. The stock currently sports a B+ Accumulation-Distribution Rating and 1.4 Up-Down Volume Ratio. Biotech Breakout Ahead? As of Wednesday's close, Exelixis was up nearly 25% for the week, with its relative strength line trending sharply higher. Volume has been well above average in recent days as the stock has retaken its 50-day line and continued to climb.
Exelixis made a huge run from a breakout last June, but the stock reset its base count in May when it undercut the low in the prior consolidation. That means its current cup-shaped pattern is considered a first-stage base. The potential buy point is 24.95. On Thursday afternoon, Exelixis had come up from earlier lows and was down just fractionally. Volume was trending about 40% above average. Look for the biotech boom to continue and for Exelixis to jump past the entry in heavy volume.
volume is good I do not understand why the stock is not moving higher any ideas?
Hairy G. Balls
how high you said? $32's ... buyout, you asked? $70's ... when you begged? FALL! boom!!!!!!!!!!!!!!!
$30 coming. Don't try to time it.
Harry Boxer has posted his Charts of the Day video on EXEL at TheTechTrader site noting: Exelixis, Inc. (EXEL) came back beautifully with a 4-day run-up right up against the prior high, popping 1,.74, or 7.8%, to 24.02, on 7.3 million shares traded. That’s the biggest volume on an up-day since February. If it gets beyond Wednesday’s high, look for it to run up toward 29.00.
EXEL becoming a beast. this sector ready to explode is what im excited about
Re: Cabo "Initial uptake of the drug was encouraging and is expected to propel the top line in the forthcoming quarters in 2017. A potential label expansion of the drug will further boost results."
Very little retail investor action at these levels. Big boy money is pouring in and will take this to the moon. We are still somewhat under valued considering a possible First line treatment for Kidney Cancer.
HERE IS THE NEXT 10 BAGGER LIKE EXEL ..THANK ME LATER IGXT (MC $46 M) NDA filing for MEGA thin-flim Cialis (better than Viagra) this month =10++ BAGGER Potential ! PLEASE read this guys and then join us to make big money .A LIFETIME OPPORTUNITY HERE GUYS !!!
2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $46 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .Load up guys before she the MEGA news hit the wire and thank me later .GL
MarketCap $46 Million Cash ~$12 Million (including convertible debt) =cash untill 2021+ Price: 0.70
NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July NDA resubmission for Rizaport (migraine) in early Q3 Partnership for Tadalafil in 2H 2017
IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.
Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.
IntelGenx has multi-faceted BD approach for its oral films
With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing